A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination

Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients

(2014) X.-F. Wang et al.   JOURNAL OF IMMUNOLOGY

Peptide Vaccination Breaks Tolerance to HER-2/neuby Generating Vaccine-Specific FasL+CD4+T Cells: First Evidence for Intratumor Apoptotic Regulatory T Cells

(2010) Angelos D. Gritzapis et al.   CANCER RESEARCH

Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy

(2010) Yann Godet et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context

(2009) Yann Godet et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Long-lasting cross-presentation of tumor antigen in human DC

(2009) Florence Faure et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple roles for CD4+T cells in anti-tumor immune responses

(2008) Richard Kennedy et al.   IMMUNOLOGICAL REVIEWS

MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency

(2008) Yann Godet et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

(2008) Naomi N. Hunder et al.   NEW ENGLAND JOURNAL OF MEDICINE